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A b s t r a c t
Background: Trans-catheter aortic valve implantation (TAVI) has recently emerged as an alternative to conventional surgery
in high-risk surgical patients with haemodynamically significant aortic valve stenosis. However, patients referred for TAVI are
usually elderly individuals (> 80 years) who frequently also suffer from renal impairment. Trans-catheter valve therapies
require extensive use of contrast injections with a risk of nephrotoxicity.
Aim: To evaluate post-TAVI renal function and to determine whether the exposure to contrast injections might cause re-
duced kidney function and contrast-induced nephropathy.
Methods: From January 2009 to September 2010, TAVI was performed in 39 patients (26 women and 13 men). The mean
age of the patients was 81.43 ± 7.39 years, and the mean volume of contrast material administered was 187.95 ± 91.34 mL.
Serum creatinine and glomerular filtration rate (GFR, acc. to the MDRD formula) were estimated in all patients prior to and
1, 2, and 5–8 days after TAVI.
Results: Two female patients died on postoperative day 1. Other patients did not show clinically significant reduction in
renal function following the procedure (mean creatinine concentration 104.46 vs 99.77 vs 94.56 vs 93.64 mmol/L, NS and
mean GFR 52.37 vs 56.63 vs 60.18 vs 61.34 mL/min/1.73 m2, NS).
Conclusions: 1. The TAVI procedure, which includes contrast injection does not seem to cause a clinically significant de-
crease of renal function. 2. None of our elderly patients with severe aortic valve stenosis, multiple co-morbidities, and pre-
TAVI renal compromise developed contrast-induced nephropathy.
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INTRODUCTION
Aortic stenosis (AS) is nowadays the most common acqu-
ired valvular lesion. The degenerative process of the aortic
valve progresses with age, hence the disease is seen most
frequently in elderly patients [1, 2]. Until recently, the only
treatment option for severe AS was surgical aortic valve
replacement. As the disease is most common in the elder-
ly, multiple co-morbidities occur, substantially increasing
operative risk. Therefore, over 30% of patients > 75 years
with severe AS are disqualified from surgical treatment [2].
Trans-catheter aortic valve implantation (TAVI) has be-
come an alternative for patients with severe AS and high ope-
rative risk (as assessed by Logistic EuroScore [> 20%] and/or
STS [> 10%]) or with other contraindications to surgical tre-
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atment, not included in these risk scores, such as porcelain
aorta [3–6]. Successful TAVI procedure improves aortic valve area
(AVA) and AVA index as well as reduces mean and maximal
trans-valvular gradient, what results in symptom reduction and
improved exercise capacity in these patients. About 70–80% of
patients live up to 2 years, co-morbidities being the main cause
of death, and quality of life is markedly improved [6–8].
The novel method of TAVI was introduced in 2002 in
France by A. Cribier, who initiated a new era in the manage-
ment of severe AS [9–13]. Unequivocal usefulness of TAVI
procedures was confirmed in the recently published PARTNER
study [14].
The TAVI is performed via either femoral, subclavian or
trans-apical access [15, 16]. The procedures are carried out
in the catheterisation laboratory, under x-ray guidance.
A potentially nephrotoxic contrast agent is injected during
the procedure [17, 18]. Patients selected for TAVI are usually
over 80 years, frequently with pre-procedural compromise
of renal function. Despite the fact that TAVI becomes a more
and more available and common treatment option for patients
with severe AS not eligible for surgery, data concerning the
effects of these procedures on renal function are scarce. The
aim of our study was to retrospectively assess renal function
in patients after TAVI.
METHODS
Between January 2009 and September 2010, 39 TAVI pro-
cedures were performed in our institution. The patients
(26 women and 13 men) aged 81.43 ± 7.39 years with severe
AS, were disqualified from surgical treatment due to high peri-
operative risk of death (Logistic EuroScore 22.19 ± 10.05%;
Table 1). All the decisions regarding patient eligibility for TAVI
were made by the Heart Team.
During TAVI, non-ionic contrast agents were used, low-
osmolar iomeprol or iso-osmolar iodixanol, in an average
dose of 187.95 ± 91.34 mL (Table 1). Iomeprol is excreted
with urine within the first 24 hours and only scarce amo-
unts are excreted within 24–38 hours from dose admini-
stration. About 80% of iodixanol is eliminated with urine
within 4 hours from intravenous administration, and 97% is
excreted within 24 hours. Only 1.2% of the dose is elimina-
ted with feces within 72 hours. The prevention of contrast
induced nephropathy (CIN) including acetylcysteine and
intravenous hydration was used in 17 patients in whom cre-
atinine clearance was < 50 mL/min/1.73 m2. In these pa-
tients, intravenous normal saline was administered one day
before and on the day of the procedure (100 mL/h, at least
4 h before the procedure), and continued for 24 hours. Intra-
venous N-acetylcysteine (NAC) at the dose of 1200 mg/d,
was also administered [19–21]. In the remaining patients only
hydration with normal saline or Ringer solution were used
peri-operatively. In diabetic patients, metformin was with-
drawn one day prior to TAVI. In each patient creatinine cle-
arance and glomerular filtration rate (GFR) according to MDRD
formula were measured one day before and 1, 2 and 5–8 days
after the procedure. The CIN was defined as serum creatini-
ne increase of 0.5 mg/dL (44 mmol/L) or by ≥ 25% of baseli-
ne value within 48 hours from contrast media administration
with the absence of alternative aetiology [17, 18].
Statistical analysis
Numerical data are expressed as means and SD. Quantitative
variables were compared with the use of Kruskall-Wallis test.
Statistical significance was set at p < 0.05.
RESULTS
Two patients died one day after TAVI: one patient died due to
native aortic ring rupture and the other due to massive ha-
emorrhage one day after the procedure. One patient was ope-
rated on due to serious gastric bleeding one day after TAVI. No
other major complications were observed. Nine patients requ-
ired pacemaker implantation in the peri-procedural period due
to multi-level conduction disturbances. In 37 patients who su-
rvived (including the patient operated on due to gastric ble-
eding), no significant deterioration of the renal function was
noted on day 1, 2 and 5–8 days post-procedurally (Figs. 1, 2).
None of the patients required renal replacement therapy.
DISCUSSION
The TAVI procedure is a relatively new method of treatment
for severe AS in patients who are not candidates for surgical
valve replacement [5, 6, 13]. During the procedure, a neph-
rotoxic contrast agent is administered, which may cause re-
nal function impairment and CIN development [17, 18].
To date, only a few studies referring to the impact of TAVI
on renal function were published. Bagur et al. [22] demon-
strated that the risk of CIN in TAVI patients was lower than in
patients undergoing conventional valve replacement surgery.
In the study of Bagur et al. [22] patients were older, had hi-
gher creatinine levels, lower GFR values and higher operative
risk as calculated by Logistic EuroScore. Even though these
patients received contrast media during TAVI, their risk of CIN
was lower than in patients undergoing conventional valve re-
placement surgery.
In our work, we did not find significant increase of cre-
atinine level or GFR reduction in any of the studied patients
either on day 1, 2 or 5–8 days post-operatively. As many as
26 patients in the study group had stage 3, and 3 subjects
had stage 4 chronic kidney disease according to the NKF
DOQI classification [23], but none of these patients had end-
stage renal disease or were dialysed. The amount of con-
trast used and peri-operative risk according to EuroScore
were lower than in other studies. This, in conjunction with
adequate hydration and NAC administration, could contri-
bute to preservation of renal function in the post-operative
period.
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Table 1. Baseline study group characteristics
Parameters Whole study group Patients with Patients with
stage 2 CKD stage 3 and 4 CKD
(GFR 60–90 ml/min/1.73 m2) (GFR 15–59 ml/min/1.73 m2)
Patients (n) 39 10 29
Sex (F/M) 26/13 4/6 22/7
Mean age [years] 81.43 ± 7.39 (62–90) 77.6 ± 9.01 (62–86) 82.76 ± 6.40 (62–90)
Coronary artery disease (n) 23 5 18
Hypertension (n) 30 8 22
Atrial fibrillation (n): 19 3 16
Chronic (n)/paroxysmal (n) 13/6 2/1 11/5
Mean LVEF [%] 53.11 ± 14.3 (30–79) 52 ± 14.95 53.52 ± 14.3
Type 2 diabetes (n) 10 4 6
COPD (n) 16 3 13
Platelets [K/mL] 167.64 ± 48.08 (66–302) 170.7 ± 49.59 (79–264) 166.59 ± 48.40 (66–302)
Hematocrite [%] 37.88 ± 4.85 (29–53.7) 39.22 ± 3.01 (33.6–44.6) 37.43 ± 5.40 (29–53.7)
Mean creatinine 104.46 ± 27.92 79.81 ± 16.13 112.96 ± 26.12
concentration [mmol/L] (49.23–173.22) (49.23–97.12) (82.32–173.22)
Mean GFR [mL/min/1.73 m2] 52.37 ± 15.04 (24–90) 73.01 ± 7.36 (63.7–90) 45.24 ± 9.18 (24–58.37)
GFR < 60 mL/min/1.73 m2 29 0 29
Acetylcysteine administration (n) 17 0 17
Mean Logistic EuroScore [%] 22.19 ± 10.05 (6.59–42.77) 19.54 ± 10.75 (6.71–38.51) 23.01 ± 9.90 (6.59–42.77)
Contrast amount [mL] 187.95 ± 91.34 (70–500) 180 ± 63.25 (100–300) 190.69 ± 100.03 (70–500)
TAVI — access:
Femoral (n) 26 7 19
Trans-apical (n) 10 2 8
Subclavian (n) 3 1 2
Valve type:
Edwards-Sapien (n) 19 6 13
CoreValve (n) 19 4 15
Balloon valvuloplasty (n) 1 0 1
CKD — chronic kidney disease; COPD — chronic obstructive pulmonary disease; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction
Figure 1. Mean creatinine level in the studied group; CKD —
chronic kidney disease
Figure 2. Mean glomerular filtration rate (GFR) in the studied
group; CKD — chronic kidney disease
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In a retrospective analysis by Aregger et al. [24], acute
CIN was observed in 28% of TAVI patients. These patients,
however, were older (by 2 years on average), had higher Euro-
Score peri-operative risk, their baseline creatinine and contrast
amount administered were higher than in our study group.
Age is one of the risk factors of CIN development. The
number of functioning glomeruli and GFR decrease with age.
Sidhu et al. [25] demonstrated that elderly women are more
prone to CIN development as compared to their male pe-
ers. As their body surface is smaller than in men, the num-
ber of glomeruli in women is also smaller what results in
earlier and more pronounced GFR reduction [25].
Strauch et al. [26] analysed 30 patients (mean age 82 ye-
ars) and EuroScore operative risk of 19% in whom TAVI was
performed and found that CIN developed in as many as 57%
of these patients; the highest creatinine levels were noted on
day 4 post-procedurally. They did not demonstrate any rela-
tionship between contrast amount, age, co-morbid diabetes
and acute kidney injury related to contrast administration. The
only variable that correlated with CIN development was coro-
nary artery disease [26]. In our group, the proportion of pa-
tients with coronary artery disease was as high as 59%, but this
seems not to have any impact on CIN incidence.
CONCLUSIONS
1. The TAVI procedure which includes contrast injection,
does not seem to cause a clinically significant decrease
of renal function.
2. None of our elderly patients with severe aortic valve ste-
nosis, multiple co-morbidities, and pre-TAVI renal com-
promise developed contrast-induced nephropathy after
the procedure.
Conflict of interest: none declared
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S t r e s z c z e n i e
Wstęp: Zabieg przezcewnikowego wszczepienia zastawki aortalnej (TAVI) jest od niedawna stosowany w leczeniu części
chorych z istotnym hemodynamicznie zwężeniem zastawki aortalnej i z wysokim ryzykiem leczenia operacyjnego. Pacjenci
kwalifikowani do TAVI to zwykle osoby starsze, przeważnie powyżej 80 rż., często z upośledzoną funkcją nerek. Jednocześ-
nie w trakcie zabiegu TAVI podaje się środek kontrastowy o działaniu nefrotoksycznym.
Cel: Celem pracy była ocena funkcji nerek po TAVI oraz zbadanie, czy podanie kontrastu podczas tego zabiegu nie prowa-
dzi do pogorszenia czynności nerek i rozwoju nefropatii pokontrastowej.
Metody: W okresie od stycznia 2009 do września 2010 roku w Instytucie Kardiologii w Warszawie metodą przezcewnikową
wszczepiono zastawkę aortalną u 39 pacjentów (26 kobiet i 13 mężczyzn) w średnim wieku 81,43±7,39 roku. Podczas
zabiegu stosowano środek kontrastowy w średniej objętości 187,95±91,34 ml o potencjalnym działaniu nefrotoksycznym.
U każdego chorego oznaczano stężenie kreatyniny i wartość przesączania kłębuszkowego wg wzoru MDRD przed TAVI oraz
w 1., 2. i 5.–8. dobie po zabiegu.
Wyniki: Dwie pacjentki zmarły w 1. dobie po zabiegu. U pozostałych chorych po TAVI nie obserwowano istotnego pogor-
szenia funkcji nerek.
Wnioski: 1. Zabieg TAVI nie pogarsza istotnie funkcji nerek. 2. W przedstawionej grupie starszych pacjentów z ciężkim
zwężeniem zastawki aortalnej, licznymi chorobami współtowarzyszącymi oraz wyjściowo upośledzoną funkcją nerek poda-
nie kontrastu podczas zabiegu TAVI nie doprowadziło do rozwoju nefropatii pokontrastowej.
Słowa kluczowe: stenoza aortalna, kontrast, niewydolność nerek, przezcewnikowe wszczepienie zastawki aortalnej
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